Investor Presentation
Respiratory Diagnostics Market Overview
Pulmonary Function Test
Accurate, but insensitive
Overview
First invented in 1846, the
advancement of the
spirometer facilitated the
early detection of pulmonary
disease in humans. The
number two lung diagnostic
in the USA with 12.2m tests
performed in 2019 (16.5% of
all lung diagnostic
procedures).
Average Estimated Cost*
Spirometry: US$72
Complete PFT: US$750
Advantages:
•
.
•
•
•
Functional
Accurate
Zero dose
Non-invasive
Low cost
(Spirometry)
O
Limitations:
TM
Volume Smyt
Pre Tri
Pre Trial
Post T
800 Pred
Insensitive as it quantifies the whole
of lung as one averaged measure
Non-specific: requires 20% variance
to be clinically significant
diagnosis
←---
late
Complete PFT is expensive and time
consuming
Effort dependent
--->>
significant
repeatability issues
Some patient cohorts have
significant issues with compliance
X-ray Technology
Inexpensive, but tells us
very little
Overview
Invented in 1895, the X-ray is
widely used in clinics to
determine changes in lung
structure. The number one lung
diagnostic in USA with 49.6m
tests performed in 2019 (66.9%
of all lung diagnostic
procedures).
Average Estimated Cost*
US$120
•
•
ÖR
Advantages:
2D image
Ubiquitous
Relatively inexpensive
Low radiation dosage
(0.1 mSv)
Limitations:
Structural, not functional
Of limited clinical value
2D image and overlapping anatomy
means features can be hidden and be
missed
Poor record in screening applications
(e.g. lung cancer, and occupational
diseases)
*Frost & Sullivan 2020.
Pg 7 Investor presentation
4DMedicalView entire presentation